{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:26:02Z","timestamp":1745468762723,"version":"3.40.4"},"reference-count":14,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>Carbohydrate antigen 19-9 (CA 19-9) is a well-known tumor marker of adenocarcinoma (reference range, 37 U\/mL). It can also be used, together with computed tomography, to monitor responses and resistance to chemotherapy in cancer patients. False elevation of CA 19-9 levels is often seen in conditions such as biliary tract obstruction and cholangitis. However, whether medication might induce false elevation of CA 19-9 levels has not yet been reported. A 74-year-old man was treated with third-line CPT-11 (irinotecan) plus panitumumab for stage IV cancer of the ascending colon. The patient developed chemotherapy-induced dysgeusia and was treated with polaprezinc. After polaprezinc administration, his CA 19-9 levels gradually increased from 18.9 to 1,699.4 U\/mL. He developed deep vein thrombosis (DVT), although it was not associated with progressive disease or metastasis. Upon discontinuation of polaprezinc, CA 19-9 levels gradually decreased. This case demonstrates that polaprezinc may not only induce false elevation of CA 19-9 levels but also cause development of DVT induced by increased CA 19-9 levels, both of which are very rare events.<\/jats:p>","DOI":"10.1159\/000503221","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T21:00:34Z","timestamp":1572037234000},"page":"163-166","source":"Crossref","is-referenced-by-count":2,"title":["Increase in Carbohydrate Antigen 19-9 Levels without Tumor Progression after Polaprezinc Administration that Induced Deep Vein Thrombosis in a Colon Cancer Patient"],"prefix":"10.1159","volume":"64","author":[{"given":"Masahito","family":"Naito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Torii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Honjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoki","family":"Hiroyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-2280-7"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2644"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2534-z"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9898"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.8533"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12633"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/154405910508400105"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.10.046"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642690"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2010.42.1.48"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/00365519850186175"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-017-0239-x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i16.5072"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30280"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/503221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/503221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:58:51Z","timestamp":1745423931000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000503221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,11,27]]},"published-print":{"date-parts":[[2019,12,3]]}},"URL":"https:\/\/doi.org\/10.1159\/000503221","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2019]]}}}